A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma

Stopped early · Phase 1

Conditions studied: Metastatic Melanoma, Malignant Metastatic Melanoma, Advanced Melanoma, Melanoma

In brief

The purpose of this study is to evaluate whether therapy with MORAb-028 is safe, effective, and to determine the appropriate dose of MORAb-028 in the treatment of metastatic melanoma.

Key facts

Study ID

NCT01212276

Run by

Morphotek

People needed

18

Starts

2010-12-01

Expected to finish

2012-09-01

Last updated by the study team

2014-07-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Measurable metastatic melanoma that has failed standard therapy
• Males and females greater than or equal to 18 years of age
• Life expectancy of greater than or equal to 3 months

You may not qualify if…

• Significant cardiovascular impairment
• Clinically significant illness, medical condition, surgical history, or laboratory abnormality that could affect the safety of the subject or negatively impact the study results
• Chemotherapy, radiotherapy, or immunotherapy within 3 weeks prior to administration to MORAb-028

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.